ITEM 1A. RISK FACTORS
 
Reference is made to the factors set forth under the caption “Forward-Looking Statements” in Part I, Item 2 of this quarterly report on Form 10-Q and other risk factors described in our annual report on Form 10-K for the year ended December 31, 2024, which are incorporated herein by reference. There have not been any material changes to the risk factors previously disclosed in our annual report on Form 10-K for the year ended December 31, 2024 and our quarterly reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025.
 
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
During January 2025, our Board of Directors authorized a share repurchase program for up to $10 billion of our outstanding common stock. During the quarter ended September 30, 2025, we repurchased 6,514,283 shares of our common stock at an average price of $383.34 per share through market purchases pursuant to the January 2025 authorization. At September 30, 2025, we had $3.256 billion of repurchase authorization available under the January 2025 authorization.
 
The following table provides certain information with respect to our repurchases of common stock from July 1, 2025 through September 30, 2025 (dollars in billions, except per share amounts).
 

Period

 

Total Number
of Shares
Purchased

 

 

Average Price
Paid per Share

 

 

Total Number
of Shares
Purchased as
Part of
Publicly
Announced
Plans or
Programs

 

 

Approximate
Dollar Value of
Shares That
May Yet Be
Purchased
Under Publicly
Announced Plans
or Programs

 

July 1, 2025 - July 31, 2025

 

 

2,175,388

 

 

$

363.47

 

 

 

2,175,388

 

 

$

4.962

 

August 1, 2025 - August 31, 2025

 

 

2,545,478

 

 

$

383.05

 

 

 

2,545,478

 

 

 

3.987

 

September 1, 2025 - September 30, 2025

 

 

1,793,417

 

 

$

407.87

 

 

 

1,793,417

 

 

$

3.256

 

Total for third quarter 2025

 

 

6,514,283

 

 

$

383.34

 

 

 

6,514,283

 

 

 

 

 
On October 23, 2025, our Board of Directors declared a quarterly dividend of $0.72 per share on our common stock payable on December 29, 2025 to stockholders of record at the close of business on December 15, 2025. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to the final determination of our Board of Directors.
 

31

 

ITEM 5. OTHER INFORMATION
 
 
(
c) During the 
three months ended September 30, 2025
, no director or officer (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934 (the “Exchange Act”)) of the Company 
adopted
 or 
terminated
 a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K. 
 
 
ITEM 6. EXHIBITS
 
(a) List of Exhibits:
 
 

 

 

 

10.1

—
 

Amendment No. 1 to Credit Agreement, dated as of October 23, 2025, by and among HCA Inc., as borrower, Bank of America, N.A., as administrative agent, and the lenders party thereto.

 

 

 

10.2
 

—
 

Amended and Restated HCA Restoration Plan, as amended through July 28, 2025.*
 

 

 

 

   22
 

—

List of Subsidiary Guarantors and Pledged Securities.
 

 

 

 

   31.1
 

—

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 

 

 

 

   31.2
 

—

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 

 

 

 

   32
 

—

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 

 

 

 

   101
 

—

The following financial information from our quarterly report on Form 10-Q for the quarter ended September 30, 2025 filed with the SEC on October 30, 2025, formatted in Inline Extensible Business Reporting Language: (i) the condensed consolidated balance sheets at September 30, 2025 and December 31, 2024, (ii) the condensed consolidated income statements for the quarters and nine months ended September 30, 2025 and 2024, (iii) the condensed consolidated comprehensive income statements for the quarters and nine months ended September 30, 2025 and 2024, (iv) the condensed consolidated statements of stockholders’ equity (deficit) for the quarters and nine months ended September 30, 2025 and 2024, (v) the condensed consolidated statements of cash flows for the nine months ended September 30, 2025 and 2024 and (vi) the notes to condensed consolidated financial statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

 

 

  104
 

—

The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Inline XBRL (included in Exhibit 101).

__________
*Management compensatory plan or arrangement.
 

32

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 

 

 

HCA Healthcare, Inc.

 

 

By:

/
S
/
 
M
ICHAEL 
A
. 
M
ARKS
 

 

Michael A. Marks

 

Executive Vice President and Chief Financial Officer

Date: October 30, 2025
 
 

33